UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
(Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code
(Former name or former address, if changed since last report.) Not applicable.
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading |
Name on each exchange on which registered | ||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 | Other Events. |
On March 25, 2024, Neuronetics, Inc. (the “Company”) posted supplemental information regarding recent clearance from the U.S. Food and Drug Administration for NeuroStar Advanced Therapy to be used as a first-line, adjunct for the treatment of major depressive disorder in adolescent patients aged 15-21. The information is posted to the Company’s website at http://ir.neuronetics.com.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
NEURONETICS, INC. | ||||||
(Registrant) | ||||||
Date: March 25, 2024 | By: | /s/ Stephen Furlong | ||||
Name: | Stephen Furlong | |||||
Title: | EVP, Chief Financial Officer and Treasurer | |||||
(Principal Financial and Accounting Officer) |
Document and Entity Information |
Mar. 25, 2024 |
---|---|
Cover [Abstract] | |
Amendment Flag | false |
Entity Central Index Key | 0001227636 |
Document Type | 8-K |
Document Period End Date | Mar. 25, 2024 |
Entity Registrant Name | NEURONETICS, INC. |
Entity Incorporation State Country Code | DE |
Entity File Number | 001-38546 |
Entity Tax Identification Number | 33-1051425 |
Entity Address, Address Line One | 3222 Phoenixville Pike |
Entity Address, City or Town | Malvern |
Entity Address, State or Province | PA |
Entity Address, Postal Zip Code | 19355 |
City Area Code | (610) |
Local Phone Number | 640-4202 |
Security 12b Title | Common Stock ($0.01 par value) |
Trading Symbol | STIM |
Security Exchange Name | NASDAQ |
Written Communications | false |
Soliciting Material | false |
Pre Commencement Tender Offer | false |
Pre Commencement Issuer Tender Offer | false |
Entity Emerging Growth Company | false |
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end
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end